Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Moving to NASDAQ once FDA designation is granted

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Feb 01, 2023 10:26am

183 Views

Post# 35259318

RE:RE:RE:RE:RE:RE:RE:Moving to NASDAQ once FDA designation is granted

I agree. I don't think there's a difference, a halt is just like a re-open. Some of a gap can be eaten up when there is a leak before a halt but in this case there should be a large gap regardless of a halt or a pre-market release.

CAinPlap wrote: I'm no expert on gaps so am curious how a halt would prevent a gap. If anything, I think it would cause one. i.e. close b4 halt at .35 and after halt, open at $3.50 is a scenario I could see happening. (for illustrative purposes only)

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages